» Articles » PMID: 15388460

DB75, a Novel Trypanocidal Agent, Disrupts Mitochondrial Function in Saccharomyces Cerevisiae

Overview
Specialty Pharmacology
Date 2004 Sep 25
PMID 15388460
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The aromatic diamidines represent a class of compounds with broad-spectrum antimicrobial activity; however, their development is hindered by a lack of understanding of their mechanism of antimicrobial action. DB75 [2,5-bis(4-amidinophenyl)furan] is a trypanocidal aromatic diamidine that was originally developed as a structural analogue of the antitrypanosomal agent pentamidine. DB289, a novel orally active prodrug of DB75, is undergoing phase IIb clinical trials for early-stage human African trypanosomiasis, Pneumocystis jiroveci carinii pneumonia, and malaria. The purpose of this study was to investigate mechanisms of action of DB75 using Saccharomyces cerevisiae as a model organism. The results of this investigation suggest that DB75 inhibits mitochondrial function. Yeast cells relying upon mitochondrial metabolism for energy production are especially sensitive to DB75. DB75 localizes (by fluorescence) within the mitochondria of living yeast cells and collapses the mitochondrial membrane potential in isolated yeast mitochondria. Furthermore, addition of DB75 to yeast cells or isolated rat liver mitochondria results in immediate uncoupling of oxidative phosphorylation and subsequent inhibition of respiration. We conclude that the mitochondrion is a cellular target of DB75 in yeast cells and anticipate that the results of this study will aid in the target-based design of new antimicrobial aromatic diamidines.

Citing Articles

Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review.

Qin Y, Wang J, Lv Q, Han B Antimicrob Agents Chemother. 2023; 67(6):e0000323.

PMID: 37195189 PMC: 10269089. DOI: 10.1128/aac.00003-23.


Visible-Light-Activated Molecular Machines Kill Fungi by Necrosis Following Mitochondrial Dysfunction and Calcium Overload.

Santos A, Beckham J, Liu D, Li G, van Venrooy A, Oliver A Adv Sci (Weinh). 2023; 10(10):e2205781.

PMID: 36715588 PMC: 10074111. DOI: 10.1002/advs.202205781.


Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents.

Wiederhold N J Fungi (Basel). 2022; 8(8).

PMID: 36012845 PMC: 9410397. DOI: 10.3390/jof8080857.


Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.

Hoenigl M, Sprute R, Arastehfar A, Perfect J, Lass-Florl C, Bellmann R Expert Opin Investig Drugs. 2022; 31(8):795-812.

PMID: 35657026 PMC: 9339492. DOI: 10.1080/13543784.2022.2086120.


Review of T-2307, an Investigational Agent That Causes Collapse of Fungal Mitochondrial Membrane Potential.

Wiederhold N J Fungi (Basel). 2021; 7(2).

PMID: 33670132 PMC: 7916847. DOI: 10.3390/jof7020130.


References
1.
Coury J, Williams L, Bottomley L . A novel assay for drug-DNA binding mode, affinity, and exclusion number: scanning force microscopy. Proc Natl Acad Sci U S A. 1996; 93(22):12283-6. PMC: 37982. DOI: 10.1073/pnas.93.22.12283. View

2.
Edwards K, Jenkins T, Neidle S . Crystal structure of a pentamidine-oligonucleotide complex: implications for DNA-binding properties. Biochemistry. 1992; 31(31):7104-9. DOI: 10.1021/bi00146a011. View

3.
Sansom C, Laughton C, Neidle S, Schwalbe C, Stevens M . Structural studies on bio-active compounds. Part XIV. Molecular modelling of the interactions between pentamidine and DNA. Anticancer Drug Des. 1990; 5(3):243-8. View

4.
Legros D, Ollivier G, Gastellu-Etchegorry M, Paquet C, Burri C, Jannin J . Treatment of human African trypanosomiasis--present situation and needs for research and development. Lancet Infect Dis. 2002; 2(7):437-40. DOI: 10.1016/s1473-3099(02)00321-3. View

5.
Bailly C, Dassonneville L, Carrasco C, Lucas D, Kumar A, Boykin D . Relationships between topoisomerase II inhibition, sequence-specificity and DNA binding mode of dicationic diphenylfuran derivatives. Anticancer Drug Des. 1999; 14(1):47-60. View